Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE We assessed ninety-six subjects (27 cognitively normal, 49 mild cognitive impairment, and 20 AD dementia) who underwent [<sup>18</sup>F]FDG and [<sup>18</sup>F]Florbetapir positron emission tomography (PET) as well as magnetic resonance imaging (MRI) with diffusion tensor imaging. 30414086 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Both 18F-FDG and 18F-florbetapir could successfully detect subjects with dementia (p < 0.001). 31322568 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE [F]FDG PET may be useful as a non-invasive diagnostic modality in differentiating the two posterior cortical dementias, despite significant overlap. 31633646 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE This study aimed to investigate the association between cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), amyloid- and <sup>18</sup>F-FDG positron emission tomography (PET) measures at baseline, in relation to cognitive changes and conversion to AD dementia over a short-term (12-month) period. 30927601 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [<sup>18</sup>F]FDG PET. 30094462 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Among the clinically implemented MRAC methods, Dixon<sub>Bone</sub> should be preferred for diagnostic assessment of dementia with [<sup>18</sup>F]FDG PET/MRI. 31446507 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Although accurate differential diagnosis of dementia can be achieved by imaging disease-specific patterns of cerebral glucose metabolism with [F]fluorodeoxyglucose ([F]FDG)-PET, the diagnostic impact of [F]FDG-PET in primary psychiatric disorders is limited. 31107281 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE However, in the opinion of the majority of the panellists, FDG PET is a clinically useful imaging biomarker for idiopathic PD and atypical parkinsonism associated with dementia. 29779045 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. 29713763 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE PET using FDG is a critical tool for evaluation of dementias, with characteristic patterns of hypometabolism suggesting specific diagnoses. 29232244 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE To update the evidence and reassess the accuracy of 18F-FDG-PET for detecting people with MCI at baseline who would clinically convert to Alzheimer's disease (AD) dementia at follow-up. 30010119 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Since fluorodeoxyglucose positron emission tomography (FDG PET) measurements of the regional cerebral metabolic rate of glucose (rCMRgl) provide a sensitive and specific marker of neurodegenerative disease progression, we sought to investigate the longitudinal pattern of rCMRgl in amyloid-positive persons with mild cognitive impairment (MCI) and dementia, hypothesizing asymmetric declines of cerebral glucose metabolism. 30101060 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE In conclusion, <sup>18</sup>F-FDG PET is a useful tool when the cause for dementia remains unclear and different diagnosis would lead to different treatment approaches. 29512075 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Qualitative agreement and diagnostic performance of arterial spin labelling MRI and FDG PET-CT in suspected early-stage dementia: Comparison of arterial spin labelling MRI and FDG PET-CT in suspected dementia. 28551486 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE At a group level, patients with AD (prodromal or dementia) showed unchanged [<sup>18</sup>F]THK5317 retention over time, in contrast to significant decreases in [<sup>18</sup>F]FDG uptake in temporoparietal areas. 28507319 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE We evaluated the utility of 18F-FDG-PET to differentiate flortaucipir tau PET negative from flortaucipir positive amnestic mild cognitive impairment and dementia and used an autopsy confirmed cohort to test the hypothesis that hippocampal sclerosis might account for the observed pattern. 29538658 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Discriminative performance (prodromal vs Alzheimer's disease dementia) of [<sup>18</sup>F]THK5317 (early-phase SUVr and R<sub>1</sub>) was compared with that of [<sup>11</sup>C]PIB (early-phase SUVr and R<sub>1</sub>) and [<sup>18</sup>F]FDG. 27107028 2017